Inhibikase Therapeutics (NYSE:IKT) vs. Alpha Cognition (OTC:ACOGF) Head to Head Review

Alpha Cognition (OTC:ACOGF) and Inhibikase Therapeutics (NYSE:IKT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, dividends, earnings and analyst recommendations.

Profitability

This table compares Alpha Cognition and Inhibikase Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
Inhibikase Therapeutics	N/A	-350.63%	-201.82%

Insider and Institutional Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 31.5% of Alpha Cognition shares are held by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Alpha Cognition has a beta of 2.8, meaning that its share price is 180% more volatile than the S&P 500. Comparatively, Inhibikase Therapeutics has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings for Alpha Cognition and Inhibikase Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alpha Cognition	0	0	2	0	3.00
Inhibikase Therapeutics	0	0	3	0	3.00

Inhibikase Therapeutics has a consensus target price of $6.00, indicating a potential upside of 204.57%. Given Inhibikase Therapeutics’ higher probable upside, analysts clearly believe Inhibikase Therapeutics is more favorable than Alpha Cognition.

Earnings and Valuation

This table compares Alpha Cognition and Inhibikase Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
Inhibikase Therapeutics	N/A	N/A	-$19.03 million	($0.39)	-5.05

Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.